Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Is Pharmacological Treatment With the Glucagon-like Peptide-1 Receptor Agonist Liraglutide 3mg (Saxenda®) Once-daily a Viable Treatment for Weight Management in Forensic Psychiatry Patients? A Feasibility Study.

NCT04781998 is registered in ClinicalTrials.gov with Anders Fink-Jensen, MD, DMSci as lead sponsor.

NCT NCT04781998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04781998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Is Pharmacological Treatment With the Glucagon-like Peptide-1 Receptor Agonist Liraglutide 3mg (Saxenda®) Once-daily a Viable Treatment for Weight Management in Forensic Psychiatry Patients? A Feasibility Study.
Lead sponsor
Anders Fink-Jensen, MD, DMSci
Phase
Phase 4
Overall status
Completed
Start date
July 1, 2021
Completion date
September 1, 2022
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

feasibility, liraglutide, mental disorder, metabolic disturbance, overweight and obesity